Nastech, Procter & Gamble form supply agreement for osteoporosis spray

By Elaine Rigoli

Tampa, Fla., June 6 - Nastech Pharmaceutical Co., Inc. and Procter & Gamble Pharmaceuticals, Inc. have entered into an agreement to manufacture and supply PTH1-34 nasal spray for the potential commercialization of this investigational product for the treatment of osteoporosis.

Specific financial terms of the agreement were not disclosed.

Under the supply agreement, Nastech will be the exclusive manufacturer of the PTH1-34 nasal spray for Procter & Gamble and will be responsible for the chemistry, manufacturing and controls sections of the FDA regulatory submission.

Nastech will manufacture the investigational product at its state-of-the-art facilities and supply it to Procter & Gamble at a transfer price that includes a manufacturing profit, according to a news release.

Procter & Gamble Pharmaceuticals, a division within Procter & Gamble Health Care, has U.S. headquarters in Cincinnati.

Nastech is a Bothell, Wash.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.